MCID: VRL011
MIFTS: 64

Viral Infectious Disease

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Viral Infectious Disease

Summaries for Viral Infectious Disease

MedlinePlus: 41 Viruses are very tiny germs. They are made of genetic material inside of a protein coating. Viruses cause familiar infectious diseases such as the common cold, flu and warts. They also cause severe illnesses such as HIV/AIDS, Ebola, and COVID-19. Viruses are like hijackers. They invade living, normal cells and use those cells to multiply and produce other viruses like themselves. This can kill, damage, or change the cells and make you sick. Different viruses attack certain cells in your body such as your liver, respiratory system, or blood. When you get a virus, you may not always get sick from it. Your immune system may be able to fight it off. For most viral infections, treatments can only help with symptoms while you wait for your immune system to fight off the virus. Antibiotics do not work for viral infections. There are antiviral medicines to treat some viral infections. Vaccines can help prevent you from getting many viral diseases.

MalaCards based summary: Viral Infectious Disease, also known as arbovirus infections, is related to lymphocytic choriomeningitis and tick-borne encephalitis, and has symptoms including fever, pruritus and pathological conditions, signs and symptoms. An important gene associated with Viral Infectious Disease is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Sirolimus and Didanosine have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and bone marrow, and related phenotypes are Strongly decreased CFP-tsO45G cell surface transport and homeostasis/metabolism

Disease Ontology: 11 A disease by infectious agent that results in infection, has material basis in Viruses.

Wikipedia: 75 A viral disease (or viral infection) occurs when an organism's body is invaded by pathogenic viruses,... more...

Related Diseases for Viral Infectious Disease

Diseases related to Viral Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2751)
# Related Disease Score Top Affiliating Genes
1 lymphocytic choriomeningitis 32.9 RIGI MAVS IRF3 IL6
2 tick-borne encephalitis 32.8 TLR3 IFNA1 CD4 CCR5
3 acute disseminated encephalomyelitis 32.7 IL6 IFNB1 CD4
4 bell's palsy 32.6 TNF TLR3 IL6 CD4
5 intermediate uveitis 32.6 TNF IL6 IL2 IFNG CD4 CCR5
6 dengue disease 32.6 TNF RIGI IL6 IL10 IFNB1 IFNA1
7 aicardi-goutieres syndrome 32.6 TNF TLR7 TLR3 RIGI MX1 MAVS
8 zika fever 32.6 TLR3 RIGI IFNB1 IFNA1
9 ebola hemorrhagic fever 32.6 TNF TLR7 TLR3 RIGI ITIH4 IRF3
10 west nile fever 32.6 TLR3 RIGI IRF3 IFNB1 IFNA1 CD4
11 chikungunya 32.6 TNF TLR7 TLR3 RIGI MAVS IL6
12 lassa fever 32.6 RIGI IRF3 IFNB1 IFNA1 IFIH1 CD4
13 influenza 32.6 TLR3 RIGI MX1 IRF7 IFNG IFNB1
14 japanese encephalitis 32.6 TLR3 RIGI IRF3 IFNB1 IFNA1 CD4
15 newcastle disease 32.6 TNF TLR3 RIGI MAVS IRF7 IRF3
16 argentine hemorrhagic fever 32.6 RIGI MAVS IRF3 IFNB1 IFNA1
17 x-linked immunodeficiency 74 32.6 TLR7 TLR3 IFNA1
18 hepatitis e 32.6 TNF TLR3 RIGI IL10 IFNG IFNB1
19 rabies 32.6 TLR3 RIGI MX1 IRF7 IRF3 IFNA1
20 hepatitis c 32.6 TLR3 RIGI MX1 MAVS IRF7 IRF3
21 hantavirus hemorrhagic fever with renal syndrome 32.6 TNF RIGI MX1 IL6 IFNB1 CD4
22 chickenpox 32.6 TNF TLR3 IL6 IL2 IL10 IFNG
23 crimean-congo hemorrhagic fever 32.6 IL6 IL10 IFNB1 IFNA1 GPT
24 measles 32.6 TLR7 TLR3 RIGI MX1 IRF7 IRF3
25 hepatitis b 32.6 TNF TLR3 RIGI MX1 IL6 IFNG
26 human cytomegalovirus infection 32.6 TNF IRF3 IL6 IL10 IFNB1 CD4
27 herpes zoster 32.6 TLR3 IL2 IL10 IFNG IFNA2 IFNA1
28 hepatitis a 32.6 TNF TLR3 MAVS IL10 IFNG IFNA2
29 coronavirus infectious disease 32.5 TNF TLR7 TLR3 RIGI IRF3 IL6
30 herpes simplex 32.5 TLR3 RIGI IRF3 IFNB1 IFNA1 IFIH1
31 mumps 32.5 TNF TLR3 MX1 IL6 IL2 IL10
32 vaccinia 32.5 TNF MAVS IRF7 IRF3 IL6 IL2
33 hand, foot and mouth disease 32.5 TLR7 TLR3 RIGI IL6 IL10 IFNG
34 anogenital venereal wart 32.5 TNF TLR7 TLR3 IL6 IL2 IFNB1
35 poliomyelitis 32.5 TNF TLR3 RIGI MAVS IRF3 IL6
36 rubella 32.5 TNF TLR3 RIGI MAVS IL6 IL2
37 progressive multifocal leukoencephalopathy 32.5 TNF IL2 IFNB1 CD4 CCR5
38 west nile encephalitis 32.5 TNF TLR7 TLR3 RIGI IL6 IL2
39 herpangina 32.5 TNF TLR7 TLR3 RIGI IL6 IL2
40 common cold 32.5 TNF TLR3 IL6 IL2 IL10 IFNB1
41 human immunodeficiency virus infectious disease 32.5 TNF TLR7 MX1 ITIH4 IRF3 IL2
42 yellow fever 32.5 RIGI IRF7 IL6 IFNB1 CCR5
43 subacute sclerosing panencephalitis 32.5 TNF TLR3 MX1 IL6 IL2 IL10
44 nasopharyngitis 32.5 TNF IL6 IFNB1 GPT
45 tropical spastic paraparesis 32.5 IL2 IFNG IFNB1 CD4
46 common wart 32.5 TLR7 IFNA1 CD4
47 monkeypox 32.5 IRF3 IFNA1 CD4
48 smallpox 32.5 TNF ITIH4 IL2 IFNG
49 hepatitis d 32.5 IFNA2 IFNA1 GPT
50 pfeiffer syndrome 32.5 TNF IL2 IL10 CD4

Graphical network of the top 20 diseases related to Viral Infectious Disease:



Diseases related to Viral Infectious Disease

Symptoms & Phenotypes for Viral Infectious Disease

UMLS symptoms related to Viral Infectious Disease:


fever; pruritus; pathological conditions, signs and symptoms

GenomeRNAi Phenotypes related to Viral Infectious Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 CCR5 CD4 GPT IFIH1 IFNA1 IFNA2
2 no effect GR00402-S-2 10.15 CCR5 CD4 IFIH1 IFNA1 IFNA2 IFNB1
3 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.73 CCR5 GPT IFIH1 MAVS TLR3 TLR7
4 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-2 9.73 CCR5 GPT IFIH1 MAVS TLR3 TLR7

MGI Mouse Phenotypes related to Viral Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CCR5 CD4 IFIH1 IFNB1 IFNG IL10
2 neoplasm MP:0002006 10.22 CCR5 IFNB1 IFNG IL10 IL2 IL6
3 immune system MP:0005387 10.21 CCR5 CD4 IFIH1 IFNA1 IFNA2 IFNB1
4 liver/biliary system MP:0005370 10.13 CCR5 IFIH1 IFNG IL10 IL2 IL6
5 cellular MP:0005384 10.1 CCR5 CD4 IFIH1 IFNG IL10 IL2
6 digestive/alimentary MP:0005381 10.07 CCR5 CD4 IFNG IL10 IL2 IL6
7 muscle MP:0005369 10.06 CCR5 IFNG IL10 IL6 MAVS TLR3
8 respiratory system MP:0005388 9.93 CCR5 IFNA1 IFNA2 IFNG IL10 IL2
9 hematopoietic system MP:0005397 9.91 CCR5 CD4 IFIH1 IFNA1 IFNA2 IFNB1
10 mortality/aging MP:0010768 9.47 CCR5 CD4 IFIH1 IFNG IL10 IL2

Drugs & Therapeutics for Viral Infectious Disease

Drugs for Viral Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 506)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
2
Didanosine Approved Phase 4 69655-05-6 50599
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
BCG vaccine Approved, Investigational Phase 4
6
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
7
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
8
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
9
Echinacea Approved, Experimental Phase 4
10
Busulfan Approved, Investigational Phase 4 55-98-1 2478
11
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
12
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
14
Rituximab Approved Phase 4 174722-31-7
15
Basiliximab Approved, Investigational Phase 4 179045-86-4
16
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
17
Clarithromycin Approved Phase 4 81103-11-9 84029
18
Valaciclovir Approved, Investigational Phase 4 124832-27-5, 124832-26-4 60773 135398742
19
Ribavirin Approved Phase 4 36791-04-5 37542
20
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
21
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
24
Copper Approved, Investigational Phase 4 7440-50-8 27099
25
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
26
Mecobalamin Approved, Investigational Phase 4 13422-55-4
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
29
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
30
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32
Tetrandrine Experimental Phase 4 518-34-3
33
Polygeline Experimental Phase 4 66455-30-9
34
Semustine Experimental, Investigational Phase 4 13909-09-6 5198
35
Cobalamin Experimental Phase 4 13408-78-1 6857388
36
Baloxavir Investigational Phase 4 1985605-59-1 138567123
37 Dextrans Phase 4
38 Adjuvants, Immunologic Phase 4
39 Interferon-alfa-1b Phase 4
40 Fluoroquinolones Phase 4
41 Antilymphocyte Serum Phase 4
42 Antibodies, Monoclonal Phase 4
43 Calcineurin Inhibitors Phase 4
44 Cyclosporins Phase 4
45
Vitamin D2 Phase 4 3249
46 Ergocalciferols Phase 4
47 Thymoglobulin Phase 4
48 Chloroquine diphosphate Phase 4 50-63-5
49 interferons Phase 4
50 Liver Extracts Phase 4

Interventional clinical trials:

(show top 50) (show all 1750)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
2 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
3 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
4 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
5 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
6 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
7 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
8 Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus Unknown status NCT03695029 Phase 4 Tenofovir Alafenamide
9 The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test and Follow-up Study Unknown status NCT01312012 Phase 4 antiviral therapy
10 Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy Unknown status NCT01289301 Phase 4 mTOR inhibitor (everolimus);cyclosporine or tacrolimus
11 Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19 Unknown status NCT04308317 Phase 4 Tetrandrine
12 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
13 Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Completed NCT02250274 Phase 4
14 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
15 Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data ("Same Day Treatment") Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection Completed NCT05606055 Phase 4 BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
16 Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
17 A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection Completed NCT00502970 Phase 4 16 weeks Interferon Tiw with Ribavirin;24 weeks Interferon
18 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
19 Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg Completed NCT00394277 Phase 4 peginterferon alfa-2a;Ribavirin
20 Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS Doses of 180 ug or 270 ug in Combination With Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater Than 85 kg Completed NCT00077649 Phase 4 ribavirin [Copegus];peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
21 Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection Completed NCT01624948 Phase 4 Everolimus;Mycophenolic acid dose reduction
22 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
23 Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study Completed NCT00935194 Phase 4 oseltamivir;chinese medicinal herbs;oseltamivir and chinese medicinal herbs
24 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Completed NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
25 PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults With Human Immunodeficiency Virus Infection Completed NCT01002040 Phase 4
26 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
27 A Randomized, Multicenter, Double Blinded Study Comparing the Safety and Efficacy of Pegasys® 180 ug Plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180 ug Plus Copegus® 800 mg in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection and HIV-1 Completed NCT00353418 Phase 4 Peginterferon alfa-2a;Ribavirin
28 A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03) Completed NCT00256828 Phase 4 didanosine + lamivudine + efavirenz
29 Randomised, Open-label, Multi-Centre, Phase IV Study Assessing the Effect of Oseltamivir Treatment on Cognitive Function in Subjects With Confirmed Influenza Virus Infection Completed NCT01249833 Phase 4 Oseltamivir
30 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
31 Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study Completed NCT01353339 Phase 4 Levofloxacin
32 A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04621461 Phase 4 Placebo
33 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
34 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
35 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
36 Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Completed NCT00981513 Phase 4
37 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Completed NCT04414267 Phase 4
38 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
39 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
40 Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients Completed NCT01789203 Phase 4 Ciprofloxacin;placebo
41 A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children Completed NCT02991872 Phase 4
42 A Stratified and Controlled Clinical Trial With Split-virion, Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Pregnant Women Completed NCT01842997 Phase 4
43 Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT03294135 Phase 4
44 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
45 Post-Marketing Clinical Study of Valaciclovir Hydrochloride Tablets -Single Oral Dose Study in Hemodialysis Patients- Completed NCT00343278 Phase 4 Valaciclovir Hydrochloride
46 A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
47 Open Clinical Trial to Assess Safety and Efficacy of the Sore Throat Lozenges in Patients With Acute Sore Throats Completed NCT04139681 Phase 4 A. Vogels Sore Throat lozenges
48 01 - GamEvac-Combi-2016 " International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose " Completed NCT03072030 Phase 4
49 Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections Completed NCT03707912 Phase 4 Anaferon;Placebo
50 International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children Completed NCT02072174 Phase 4 Anaferon for Children

Search NIH Clinical Center for Viral Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
Idoxuridine
Nucleoside Analog Antiviral [EPC]
Ribavirin
Trifluridine

Cochrane evidence based reviews: arbovirus infections

Genetic Tests for Viral Infectious Disease

Anatomical Context for Viral Infectious Disease

Organs/tissues related to Viral Infectious Disease:

MalaCards : T Cells, Liver, Bone Marrow, Kidney, Lung, Cervix, Bone

Publications for Viral Infectious Disease

Articles related to Viral Infectious Disease:

(show top 50) (show all 75277)
# Title Authors PMID Year
1
Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis. 62 41
36459252 2022
2
Oxidative stress and viral Infections: rationale, experiences, and perspectives on N-acetylcysteine. 62 41
36459039 2022
3
Impact of non-pharmaceutical interventions targeted at the COVID-19 pandemic on the incidence of influenza-like illness in the UK Armed Forces. 41
36454952 2022
4
Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. 53 62
20368393 2010
5
IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. 53 62
20440075 2010
6
Oxidative stress enhances toll-like receptor 3 response to double-stranded RNA in airway epithelial cells. 53 62
19597128 2010
7
Interleukin-4 downregulates CD127 expression and activity on human thymocytes and mature CD8+ T cells. 53 62
20201040 2010
8
Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. 53 62
20038212 2010
9
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. 53 62
20334827 2010
10
Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. 53 62
19806318 2010
11
Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. 53 62
20040578 2010
12
Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. 53 62
20044805 2010
13
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. 53 62
20208540 2010
14
MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. 53 62
20130213 2010
15
Restriction of feline retroviruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha proteins. 53 62
19896724 2010
16
Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). 53 62
20042501 2010
17
Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner. 53 62
19906941 2010
18
Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. 53 62
20005910 2010
19
Tumor necrosis factor blockade and the risk of viral infection. 53 62
20142812 2010
20
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. 53 62
20028826 2010
21
Temporal association of large granular lymphocytosis, neutropenia, proviral load, and FasL mRNA in cats with acute feline immunodeficiency virus infection. 53 62
19896217 2010
22
IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. 53 62
20212069 2010
23
Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. 53 62
19955313 2010
24
Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. 53 62
20121403 2010
25
Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. 53 62
19955307 2010
26
Serum IL-18 and IL-18BP levels in patients with Chikungunya virus infection. 53 62
20121409 2010
27
Viral induction of the zinc finger antiviral protein is IRF3-dependent but NF-kappaB-independent. 53 62
20048147 2010
28
Preparation of polyclonal antibody against human MxA protein and its specificity to diversified myxovirus resistant protein A. 53 62
20486440 2010
29
[Contemporary threat of influenza virus infection]. 53 62
20369714 2010
30
Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. 53 62
19837110 2010
31
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. 53 62
20025530 2010
32
Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. 53 62
19828602 2010
33
Toll-like receptor 7 function is reduced in adolescents with asthma. 53 62
19643938 2010
34
Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. 53 62
19864382 2010
35
Intracellular staining for analysis of the expression and phosphorylation of signal transducers and activators of transcription (STATs) in NK cells. 53 62
20033640 2010
36
Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. 53 62
19833099 2009
37
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. 53 62
19937696 2009
38
Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? 53 62
20034255 2009
39
Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? 53 62
19950271 2009
40
Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report. 53 62
20044643 2009
41
Expression of an IKKgamma splice variant determines IRF3 and canonical NF-kappaB pathway utilization in ssRNA virus infection. 53 62
19956647 2009
42
Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. 53 62
19656161 2009
43
Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. 53 62
19910749 2009
44
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. 53 62
19846870 2009
45
Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem. 53 62
19732028 2009
46
The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in a Chinese population. 53 62
19744071 2009
47
Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. 53 62
19740379 2009
48
Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. 53 62
19362523 2009
49
Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report. 53 62
19653058 2009
50
ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. 53 62
19605474 2009

Variations for Viral Infectious Disease

Expression for Viral Infectious Disease

Search GEO for disease gene expression data for Viral Infectious Disease.

Pathways for Viral Infectious Disease



Pathways directly related to Viral Infectious Disease:

# Pathway Source
1 HCMV Infection Reactome 66
2 HCMV Late Events Reactome 66
3 Potential therapeutics for SARS Reactome 66
4 HCMV Early Events Reactome 66
5 Microbial modulation of RIPK1-mediated regulated necrosis Reactome 66

Pathways related to Viral Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TNF TLR7 TLR3 RIGI MX1 MAVS
2
Show member pathways
13.88 TLR7 TLR3 RIGI MAVS IRF7 IRF3
3
Show member pathways
13.7 TNF IL6 IL2 IL10 IFNG IFNB1
4
Show member pathways
13.61 CD4 IFNA1 IFNA2 IFNB1 IFNG IL10
5
Show member pathways
13.48 CCR5 CD4 IL10 IL2 IL6 TLR3
6
Show member pathways
13.4 TNF RIGI MX1 IRF7 IRF3 IL6
7
Show member pathways
13.33 TLR7 RIGI MAVS IRF7 IRF3 IFNB1
8
Show member pathways
12.83 TNF TLR7 TLR3 RIGI MX1 MAVS
9
Show member pathways
12.76 TNF TLR7 TLR3 IL6 IL2
10
Show member pathways
12.72 CCR5 IFNA1 IFNA2 IFNB1 IFNG IL10
11
Show member pathways
12.68 TNF IL6 IL2 IL10 IFNG CD4
12
Show member pathways
12.68 RIGI MX1 IRF7 IRF3 IFNG IFNB1
13
Show member pathways
12.67 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
14 12.61 TNF TLR7 TLR3 RIGI MAVS IRF7
15
Show member pathways
12.59 TLR7 RIGI MAVS IRF3 IFIH1
16
Show member pathways
12.59 TLR3 RIGI MAVS IRF7 IRF3 IL6
17
Show member pathways
12.59 TLR3 RIGI MAVS IRF7 IRF3 IFNG
18
Show member pathways
12.5 TNF TLR7 IL6 IFNG IFNB1
19
Show member pathways
12.4 TNF TLR3 IRF3 IL6 IFNG
20
Show member pathways
12.3 TLR7 TLR3 IRF7 IRF3
21 12.29 TNF TLR7 TLR3 IL6 IFNG
22
Show member pathways
12.29 TNF IL2 IL10 IFNG IFNB1 CD4
23 12.18 TNF IL6 IL10 IFNG
24 12.18 CD4 IFNA2 IFNG IL10 IL2 IL6
25
Show member pathways
12.1 CD4 IFNG IL10 IL2 IL6 TLR3
26 12.08 TNF IL6 IL2 IFNG
27
Show member pathways
12.06 IL2 IFNG CD4 CCR5
28
Show member pathways
12.04 IRF3 IFNB1 IFNA2 IFIH1 IRF7 MAVS
29 12.03 IRF7 IL6 IFNG IFNB1
30 12.01 IFNA1 IFNA2 IFNB1 IFNG IL6
31
Show member pathways
12 CD4 IFNG IL6 TLR3 TLR7
32 11.97 IFNG IL10 IL2 TNF
33 11.97 TLR3 IL6 IL2 IL10 IFNG CD4
34 11.94 TNF IL2 IL10 IFNG CD4
35
Show member pathways
11.9 TNF IRF3 IFNG IFNB1
36 11.9 TNF TLR7 IL6 IL2 IL10 IFNG
37
Show member pathways
11.88 MAVS IL6 IFNB1 CD4
38 11.87 TNF IL6 IFNB1 IFNA2
39 11.83 IFNG IL10 IL2 IL6
40 11.82 CD4 IFNG IL2 IL6
41 11.82 TNF TLR7 IRF7 IL6 IL10
42 11.81 IL6 IL2 IFNG
43 11.79 IRF7 IL10 IFNB1
44
Show member pathways
11.79 IFNG IL10 IL2 IL6 TNF
45
Show member pathways
11.78 TNF IL6 IL2 IFNG
46
Show member pathways
11.75 TNF IL2 IFNG
47 11.71 TNF IL6 IL10
48 11.68 TNF IL6 IFNG IFNA2
49 11.68 CD4 IFNA2 IFNB1 IFNG IL10 IL2
50 11.66 TNF IL2 IL10 IFNG CD4

GO Terms for Viral Infectious Disease

Cellular components related to Viral Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.62 TNF TLR3 ITIH4 IL6 IL2 IL10

Biological processes related to Viral Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.65 IFNB1 IL10 IL2 IL6 IRF3 IRF7
2 signal transduction GO:0007165 10.59 CCR5 CD4 IFNG IL10 IL6 MAVS
3 innate immune response GO:0045087 10.52 IFIH1 IRF3 IRF7 MAVS MX1 RIGI
4 adaptive immune response GO:0002250 10.49 IL2 IFNG IFNB1 IFNA2 IFNA1 CD4
5 inflammatory response GO:0006954 10.44 TNF TLR7 TLR3 IL6 IFNA2 CCR5
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.38 CD4 IRF3 MAVS TLR3 TNF
7 positive regulation of tumor necrosis factor production GO:0032760 10.35 TLR3 RIGI MAVS IL6 IFNG IFIH1
8 positive regulation of DNA-binding transcription factor activity GO:0051091 10.34 TNF RIGI MAVS IL6 IL10
9 positive regulation of inflammatory response GO:0050729 10.33 IFNG IL2 TLR3 TLR7 TNF
10 cytosolic pattern recognition receptor signaling pathway GO:0002753 10.32 RIGI IFIH1
11 cytosolic pattern recognition receptor signaling pathway GO:0039528 10.32 RIGI IFIH1
12 immune response GO:0006955 10.31 TNF TLR7 TLR3 IL6 IL2 IL10
13 positive regulation of interleukin-6 production GO:0032755 10.31 TNF TLR7 TLR3 RIGI MAVS IL6
14 positive regulation of interleukin-8 production GO:0032757 10.3 TNF TLR7 TLR3 RIGI MAVS IL6
15 B cell differentiation GO:0030183 10.29 IL10 IFNB1 IFNA2 IFNA1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.29 TNF IL6 IL2 IFNG IFNA2
17 humoral immune response GO:0006959 10.29 IFNA1 IFNA2 IFNB1 IFNG IL6 TNF
18 positive regulation of type II interferon production GO:0032729 10.26 IL2 TLR3 TLR7 TNF
19 cellular response to lipopolysaccharide GO:0071222 10.26 TNF IRF3 IL6 IL10 CCR5
20 positive regulation of chemokine production GO:0032722 10.26 TNF TLR7 TLR3 IL6 IFNG
21 immune system process GO:0002376 10.26 TLR7 TLR3 RIGI MX1 MAVS IRF7
22 negative regulation of viral genome replication GO:0045071 10.25 IFIH1 IFNB1 MAVS MX1 TNF
23 B cell proliferation GO:0042100 10.23 IL10 IFNB1 IFNA2 IFNA1
24 type I interferon-mediated signaling pathway GO:0060337 10.23 IFNA1 IFNA2 IFNB1 IRF3 IRF7 MAVS
25 regulation of insulin secretion GO:0050796 10.2 TNF IL6 IFNG
26 response to activity GO:0014823 10.2 TNF IL6 IL10
27 positive regulation of cytokine production GO:0001819 10.2 TNF TLR3 IRF3 IL10 IFNG
28 MAPK cascade GO:0000165 10.19 TNF TLR7 TLR3 CCR5
29 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.18 TNF IL6 IL10
30 liver regeneration GO:0097421 10.18 TNF IL6 IL10
31 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 10.18 IFNA1 IFNA2 IFNB1 IFNG
32 positive regulation of immunoglobulin production GO:0002639 10.17 IL10 IL2 IL6
33 response to exogenous dsRNA GO:0043330 10.17 TLR3 RIGI IRF3 IFNB1 IFNA2 IFNA1
34 positive regulation of interferon-beta production GO:0032728 10.17 TLR7 TLR3 RIGI MAVS IRF7 IRF3
35 microglial cell activation GO:0001774 10.16 TNF TLR3 IFNG
36 T cell activation involved in immune response GO:0002286 10.16 IFNB1 IFNA2 IFNA1
37 response to virus GO:0009615 10.16 IFIH1 IFNB1 IFNG IRF7 MAVS MX1
38 cellular response to exogenous dsRNA GO:0071360 10.15 IFIH1 IFNB1 IRF3 MAVS RIGI TLR3
39 positive regulation of type I interferon-mediated signaling pathway GO:0060340 10.13 MAVS IRF7 IRF3
40 natural killer cell activation involved in immune response GO:0002323 10.12 IFNB1 IFNA2 IFNA1
41 positive regulation of response to cytokine stimulus GO:0060760 10.1 RIGI MAVS IFIH1
42 defense response GO:0006952 10.1 TNF TLR3 MX1 IFNB1 IFNA2 IFNA1
43 detection of virus GO:0009597 10.09 TLR3 RIGI IFIH1
44 antiviral innate immune response GO:0140374 10.07 RIGI MX1 IFIH1
45 MDA-5 signaling pathway GO:0039530 10.06 IRF7 IRF3 IFIH1
46 negative regulation of macrophage apoptotic process GO:2000110 10.02 IRF7 CCR5
47 negative regulation of cytokine production involved in immune response GO:0002719 10.01 TNF IL10
48 negative regulation of T-helper 2 cell cytokine production GO:2000552 10.01 IFNA2 IFNB1
49 positive regulation of plasma cell differentiation GO:1900100 10 IL2 IL10
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 10 TNF IFNG

Molecular functions related to Viral Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 single-stranded RNA binding GO:0003727 9.8 TLR7 RIGI IFIH1
2 double-stranded RNA binding GO:0003725 9.76 TLR7 TLR3 RIGI IFIH1
3 cytokine receptor binding GO:0005126 9.56 IFNB1 IFNA2 IFNA1
4 cytokine activity GO:0005125 9.53 TNF IL6 IL2 IL10 IFNG IFNB1
5 type I interferon receptor binding GO:0005132 9.43 IFNB1 IFNA2 IFNA1

Sources for Viral Infectious Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....